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Antibiotic resistance – from pathogen to disease surveillance
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Surveillance is central to defining the epidemiology of antibiotic resistance, developing
new strategies for its control, informing disease management, identifying targets for new
drugs and vaccines and in turn, evaluating and refining the impact of these interventions.
Current surveillance systems often fall short of this ideal. Since antibiotics are prescribed
for the treatment of specific disease, surveillance that reliably links diagnosis, pathogen
and antibiotic usage is likely to be more informative. By identifying diseases that are
readily recognized, and are usually reliably defined microbiologically, and in turn have
clear links to public-health issues, a broader ownership of surveillance data should result.
The case is argued for a more disease-focused microbiological surveillance approach than
exists at present. Examples are provided which reflect a cross-section of community,
nosocomial, zoonotic and imported infectious disease challenges, and where new
approaches are urgently required to combat the upward spiral of resistance.
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Great strides have been made in raising profes-
sional, public and political awareness of the many
concerns surrounding resistance to antibiotics.
Much has been written in defining the problem
and in developing strategic initiatives targeted at
its control [1–3]. Indeed, there is some glimmer of
hope that all this effort may be paying dividends in
relation to antibiotic consumption in some coun-
tries (R. Tiner, Pers. comm.) and yet there remains
uncertainty as to how effectively the strategies
aimed at encouraging ‘prudent prescribing’ and
better education of the public will contain this
problem.
Antibiotic resistance surveillance is central to
defining the frequency, distribution and dynamics
of resistance among organisms pathogenic to man
and animals. It is also the basis on which control
strategies, such as prescribing support systems,
guidelines and policies for antibiotic use are devel-
oped, while also identifying areas for better
hygienic control of disease. It also provides the
stimulus for new technologies, such as novel vac-
cines or antimicrobial agents. Furthermore, sur-
veillance is a yardstick by which the success or
failure of any strategy might be judged and
refined.
There is no shortage of surveillance of bacteria
and their susceptibility to antimicrobial agents.
Indeed, it is difficult for the specialist to keep
abreast of the plethora of current systems, as well
as to understand their design, focus and outputs.
Some surveillance schemes deal with a single
genus, such as Legionella, Mycobacterium spp., or
enteric pathogens, while others cover a range of
organisms relevant to a single body site, such as
infections of the bloodstream, lower respiratory
tract, or urinary tract.
The shortcomings of the current approaches to
the surveillance of antibiotic resistance are better
recognized and are, in part, being addressed [4].
These extend from the selective nature of sampling
(What prompts a patient to seek medical attention?
What prompts the clinician to carry out microbio-
logical sampling?), specimen quality and proces-
sing, the lack of standardized international
methodologies and variations in breakpoints for
susceptibility testing. Despite the recognition of
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the need for denominator-based data for health-
care planning, this remains an uncommon feature
of many surveillance systems. Furthermore, the
minimum data-set necessary to monitor trends in
resistance lacks definition. Should surveillance be
continuous, intermittent, seasonal or based on a
defined fraction of isolates? While antibiotic use
and resistance are linked, the precise manner in
which this arises in relation to a specific drug and
pathogen is often unclear. Attempts to link anti-
biotic resistance surveillance to antibiotic use are
somewhat belatedly emerging and should permit
a greater understanding and prompt more rational
recommendations for empirical prescribing [5].
The growing number of international surveil-
lance systems are largely commercially funded.
Some are designed to collect data on pathogens
relevant to the marketing ambitions of a particular
antibiotic, whilst others capture routine laboratory
data which is made available to the contributing
laboratories without charge, but to others at a cost.
There is limited evidence that these commercial
systems have generated outputs beyond describ-
ing resistance trends internationally. The metho-
dological problems cited previously are likely to
be magnified by this global approach even though
laboratory methodologies for susceptibility testing
are usually standardized. Reassurance that there is
concordance of the data generated by geographi-
cally overlapping surveillance systems would be
welcome.
Surveillance data are largely pathogen-focused
rather than disease-directed and yet antibiotics are
primarily prescribed for the management of infec-
tious disease. Should surveillance systems be
adapted to provide data that have a greater focus
on disease management? Surveillance certainly
needs to be designed around a strategy for contain-
ing antibiotic resistance, be it through education,
prescribing policies, promotion of hygienic mea-
sures or through drug innovation. It should not be
an end in itself. By shifting the emphasis from the
surveillance of micro-organisms to one of disease
management, the prescriber is more likely to have
ownership of recommendations that encourage
prudent prescribing. Will this require novel noti-
fication systems, or can the currently collected
surveillance data be used more effectively? By
selecting diseases for which microbiological sur-
veillance data are important, it should still be
possible to capture information on the dynamics
of drug resistance. In other words, by collecting
data from patients with defined diseases, not only
will microbiological information relevant to indi-
vidual patient management be derived, but also
data that inform us of the epidemiology of the
target disease.
Currently, there are concerns surrounding the
issues of multidrug-resistant tuberculosis, hospi-
tal-acquired infection, the escalating burden of
drug-resistant pneumococcal disease as well as
zoonotic and food-borne infections. Antibiotics
play either an integral or occasional role in mana-
ging such diseases. In response to these concerns it
is proposed that among the diseases which might
benefit from this approach to surveillance are
meningitis, bloodstream infections, urinary tract
infections, bacterial enteritis, surgical wound
infections and tuberculosis. The basis for selecting
these diseases is that they are conditions for which
a microbiological diagnosis is readily established
and refinements to current surveillance systems
are likely to be relatively modest.
Bacterial meningitis is a life-threatening com-
munity infection which is generally managed in
hospital. Streptococcus pneumoniae and Neisseria
meningitidis are numerically the major pathogens
for which resistance to penicillin has emerged in
the first case and close monitoring in anticipation
of a future problem is required in the second.
Furthermore, such isolates have a proven pedigree
of virulence. Both are also targets for better vaccine
control of diseases. In the case of S. pneumoniae,
reliable information on susceptibility to penicillin
will not only guide individual patient manage-
ment, but will aid the establishment of optimal
therapeutic regimens. At present, there is no clear
guidance as to what frequency of antibiotic resis-
tance among target pathogens should alter the
initial empirical antibiotic regimens in the man-
agement of specific diseases. Additional benefits
from a more robust disease-focused surveillance
approach might be derived from typing of isolates
causing meningitis in order to support the intro-
duction and monitor the effectiveness of current
and future vaccines.
Bloodstream infections complicate a variety
of community and hospital-acquired infections.
Again, the isolates are of proven virulence
which distinguishes them from non-invasive or
colonizing micro-organisms. By applying optimal
microbiological speciation and selected typing of
isolates, maximum clinical utility could be
derived. This not only guides empirical and
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definitive treatment policies but also provides
information on hospital-acquired infections in
order to aid epidemic recognition and support
infection control measures.
Most episodes of pulmonary tuberculosis are
investigated and the contacts are traced. The clin-
ical diagnosis is usually confirmed microbiologi-
cally. This information is collected nationally and
internationally and provides valuable information
on epidemiology and trends in resistance. Such
data are also valuable as pointers to imported
disease from countries in which tuberculosis
and, in particular, drug-resistant diseases, may
be more common. Furthermore, as the incidence
of drug-resistant tuberculosis increases, so will the
legacy to future populations who will increasingly
succumb to drug-resistant disease unless tubercu-
losis is more effectively controlled. Robust surveil-
lance data are also essential for health-care
planning, since tuberculosis remains a useful bar-
ometer of the socio-economic health of a nation. It
is also an increasingly important stimulus to
research, both in relation to new diagnostics and
to novel therapeutic approaches.
Bacterial enteritis resulting from Salmonella,
Campylobacter or Shigella infection is a major health
problem which figures prominently among the
eight million estimated annual cases of food-asso-
ciated disease in the UK. Good surveillance data
have several functions. While only a minority of
those affected will require antibiotic management,
susceptibility data are invaluable in the initial
empirical and definitive management of invasive
salmonellosis. More importantly, such data pro-
vide a yardstick for measuring an important group
of zoonotic infections, as well as monitoring the
effectiveness of food safety regulations both in
relation to home and imported food products
[6].
Infections of the urinary tract are reliably con-
firmed microbiologically. The causative organisms
generally arise from the perineal flora, which in
turn reflects that of the bowel. High-quality sur-
veillance data not only support individual patient
management, but also guide the selection of initial
empirical therapy, which can be tailored to com-
munity- or hospital-managed infections. Valuable
epidemiological data on drug resistance can also
accrue since the bowel flora is a sensitive indicator
of the selective pressures resulting from antibiotic
use within either the community or hospital set-
ting [6]. Susceptibility data on urinary isolates
could also be used more effectively in disease
management. Instead of presenting data in rela-
tion to urinary tract infections simply in terms of
susceptibility trends of individual pathogens, such
as Escherichia coli, data could be reported as a
composite of susceptibilities of urinary isolates
from defined populations. This would better sup-
port prescribing advice and perhaps define at
what level of resistance the choice of initial empiri-
cal therapy should change. For example, if an
overall resistance rate of 10% were to be set, then
clinical studies could be conducted to assess the
benefit of such guidance.
One final clinical problem for which disease-
focused microbiological surveillance data could
more effectively support management is that of
surgical wound infections. Infected wounds are
regularly sampled (often by nursing staff applying
agreed protocol care). Wound infections arising
after discharge are less regularly sampled. In addi-
tion to guiding clinicians on antibiotic manage-
ment, when this is indicated, such data could also
provide a valuable audit of good clinical practice
and hospital hygiene, as well as monitoring epi-
demic nosocomial infections. The current concerns
surrounding methicillin-resistant Staphylococcus
aureus, an increasingly common isolate from sur-
gical wound infections in some centers, is a parti-
cular issue that could be addressed. By combining
data-sets from surgical wound and bloodstream
infections, and deriving greater discrimination of
isolates through molecular typing, more virulent
epidemic isolates could be identified.
In summary, by directing microbiological sur-
veillance to support disease management, it is
anticipated that ownership of resistance surveil-
lance data would be improved and more effective
guidance on empirical antibiotic use could result.
Health-care planning is more usually focused
around disease management than around patterns
of susceptibility of target micro-organisms. By
adapting and improving current surveillance sys-
tems, more effective control strategies directed at
disease management, including antibiotic use and
hospital hygiene, might be developed and tested.
Educational activities aimed at health-care profes-
sionals and the public would have a greater rele-
vance and would be measurable. In addition,
answers may emerge on what and how much
microbiological surveillance is necessary to sup-
port disease management. At a time when local,
national and international surveillance systems
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are mushrooming, often without clearly stated
objectives, it is important that these issues be
debated. Furthermore, the financial investment
in surveillance could more readily be justified,
targets established and outcomes measured. It is
time that surveillance moves beyond describing
the problem of resistance and moves towards a
disease contol approach.
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